NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a K d of 16 nM and an IC 50 of 27 nM (in Hela cells). Anti-tumor activity In Vivo NMS-P515 (80 mg/kg, orally daily for 12 days) exhibits potent antitumor activity in mouse models based pancreatic cancer . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Subcutaneously implanted Capan-1 pancreatic (BRCA2-mutated) mouse xenografts . Dosage: 80 mg/kg. Administration: Orally, once daily for 12 days. Result: Clearly reduced the tumor growth (maximal tumor growth inhibition observed: 48%, maximum body weight loss: 6%). Form:Solid IC50& Target:PARP-1 16 nM (Kd) PARP-1 27 nM (IC 50 , in Hela cells)